肠道菌群对桃鞣花单宁的代谢差异影响健康产出吗?
创作:FU 审核:JIAN 剑 2017年12月15日
  • 尿石素类化合物是肠道菌群代谢鞣花单宁产生的六羟基联苯二酸衍生物;根据个人代谢类型的不同,分为UM-A,UM-B和UM-0型。
  • 本文对不同体重指数及代谢综合征患者的血清生化指标进行分析,发现代谢型和心血管代谢风险(CMR)因子之间存在关联。
  • UM-A与载脂蛋白A-1、中间密度-高密度脂蛋白胆固醇水平显著正相关。
  • UM-B和UM-A异构体是与CMR相关的生物标志物。
  • 未来需要开展大规划队列研究,论证代谢型对降脂药和鞣花单宁作用的影响。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!
图片
Clinical Nutrition [IF:6.402]

The gut microbiota metabolism of pomegranate or walnut ellagitannins yields two urolithin-metabotypes that correlate with cardiometabolic risk biomarkers: Comparison between normoweight, overweight-ob

石榴或核桃鞣花单宁在肠道菌群代谢下产生两种与心血管代谢疾病风险相关的尿石素类代谢产物

10.1016/j.clnu.2017.03.012

2017-03-04, Article

Abstract & Authors:展开

Abstract:收起
BACKGROUND & AIMS: Urolithins are microbial metabolites produced after consumption of ellagitannin-containing foods such as pomegranates and walnuts. Parallel to isoflavone-metabolizing phenotypes, ellagitannin-metabolizing phenotypes (urolithin metabotypes A, B and 0; UM-A, UM-B and UM-0, respectively) can vary among individuals depending on their body mass index (BMI), but correlations between urolithin metabotypes (UMs) and cardiometabolic risk (CMR) factors are unexplored. We investigated the association between UMs and CMR factors in individuals with different BMI and health status.
METHODS: UM was identified using UPLC-ESI-qToF-MS in individuals consuming pomegranate or nuts. The associations between basal CMR factors and the urine urolithin metabolomic signature were explored in 20 healthy normoweight individuals consuming walnuts (30 g/d), 49 healthy overweight-obese individuals ingesting pomegranate extract (450 mg/d) and 25 metabolic syndrome (MetS) patients consuming nuts (15 g-walnuts, 7.5 g-hazelnuts and 7.5 g-almonds/d).
RESULTS: Correlations between CMR factors and urolithins were found in overweight-obese individuals. Urolithin-A (mostly present in UM-A) was positively correlated with apolipoprotein A-I (P ≤ 0.05) and intermediate-HDL-cholesterol (P ≤ 0.05) while urolithin-B and isourolithin-A (characteristic from UM-B) were positively correlated with total-cholesterol, LDL-cholesterol (P ≤ 0.001), apolipoprotein B (P ≤ 0.01), VLDL-cholesterol, IDL-cholesterol, oxidized-LDL and apolipoprotein B:apolipoprotein A-I ratio (P ≤ 0.05). In MetS patients, urolithin-A only correlated inversely with glucose (P ≤ 0.05). Statin-treated MetS patients with UM-A showed a lipid profile similar to that of healthy normoweight individuals while a poor response to lipid-lowering therapy was observed in MB patients.
CONCLUSIONS: UMs are potential CMR biomarkers. Overweight-obese individuals with UM-B are at increased risk of cardiometabolic disease, whereas urolithin-A production could protect against CMR factors. Further research is warranted to explore these associations in larger cohorts and whether the effect of lipid-lowering drugs or ellagitannin-consumption on CMR biomarkers depends on individuals' UM.
CLINICAL TRIAL REGISTRY NUMBERS AND WEBSITES: NCT01916239 (https://clinicaltrials.gov/ct2/show/NCT01916239) and ISRCTN36468613 (http://www.isrctn.com/ISRCTN36468613).

First Authors:
María V Selma, Juan C Espín

Correspondence Authors:
María V Selma

All Authors:
María V Selma,Antonio González-Sarrías,Jordi Salas-Salvadó,Cristina Andrés-Lacueva,Cesarettin Alasalvar,Asım Örem,Francisco A Tomás-Barberán,Juan C Espín

评论